计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C338042-1mg |
1mg |
现货 ![]() |
| |
| C338042-5mg |
5mg |
现货 ![]() |
| |
| C338042-10mg |
10mg |
现货 ![]() |
| |
| C338042-25mg |
25mg |
现货 ![]() |
| |
| C338042-50mg |
50mg |
现货 ![]() |
| |
| C338042-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | HDAC-IN-7 | HBI-8000;CS-055 | N-(2-amino-5-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide | (E)-N-(2-amino-5-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Chidamide impurity |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 组蛋白去乙酰化酶 1 抑制剂 |
| 产品介绍 |
HDAC-IN-7 (HBI-8000) 是 Chidamide 的一种杂质。Chidamide 是一种 HDAC 酶 I 类 HDAC1/2/3 和 IIb 类 HDAC10 抑制剂. Chidamide is an HDAC (histone deacetylase) inhibitor that increases histone H3 acetylation levels in LoVo and HT29 colon cancer cells at concentrations as low as 4 μM. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-(2-amino-5-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide |
| INCHI | 1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+ |
| InChi Key | WXHHICFWKXDFOW-BJMVGYQFSA-N |
| Smiles | C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=CC(=C3)F)N |
| Isomeric SMILES | C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=CC(=C3)F)N |
| 关联CAS | 1883690-47-8 |
| 分子量 | 390.41 |
| Reaxy-Rn | 20992484 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20992484&ln= |
| 溶解性 | Soluble in DMSO (~20 mg/ml), DMF (~20 mg/ml), and 1: 1 DMSO: PBS(pH 7.2) (~0.5 mg/ml). |
|---|---|
| 密度 | ~1.34 g/cm3(Predicted) |
| 折光率 | n20D1.69 (Predicted) |
| 沸点 | ~600.16° C at 760 mmHg (Predicted) |
| 熔点 | 284.63° C (Predicted) |
| 分子量 | 390.400 g/mol |
| XLogP3 | 2.300 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 390.149 Da |
| 单同位素质量Monoisotopic Mass | 390.149 Da |
| 拓扑极表面积Topological Polar Surface Area | 97.100 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 577.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 | |
| 分析证书 | C338042 |
| 1. Liu L, Chen B, Qin S, Li S, He X, Qiu S, Zhao W, Zhao H. (2010) A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.. Biochem Biophys Res Commun, 392 (2): (190-5). [PMID:20060381] |
| 2. Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. (2012) Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.. Cancer Chemother Pharmacol, 69 (6): (1413-22). [PMID:22362161] |
| 3. Gong K, Xie J, Yi H, Li W. (2012) CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.. Biochem J, 443 (3): (735-46). [PMID:22339555] |
| 4. Wang H, Guo Y, Fu M, Liang X, Zhang X, Wang R, Lin C, Qian H. (2012) Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.. Mol Med Rep, 5 (6): (1503-8). [PMID:22484326] |
| 5. Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, Sun L, He Y, Ge Y, Yu Q. (2013) Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.. Biochem Biophys Res Commun, 434 (1): (95-101). [PMID:23541946] |
| 6. Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L, Yu L. (2013) Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.. PLoS ONE, 8 (8): (e70522). [PMID:23940586] |
| 7. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C et al.. (2019) Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet Oncol, 20 (6): (806-815). [PMID:31036468] |